Australia Inks Next-Gen mRNA Technology Deal With US

Commonwealth Serum Laboratories (CSL), an Australian biotechnology company and the world’s second-largest vaccine maker, has agreed to pay $US312 million ($US200 million) to use the US company’s disruptive mRNA vaccine technology.

The vaccine manufacturer announced on Nov. 2 and he licensed new technology to Arcturus Therapeutics, an American mRNA biotechnology company.

“This partnership is an exciting opportunity to complement CSL’s mRNA generation program with a partner that has developed a platform to deliver early clinical applications at scale,” CSL Chief Operating Officer Paul McKenzie said in a statement.

“These combined capabilities will enhance our journey to mRNA.”

Arcturus’ mRNA vaccines use “self-proliferation” technology that studies have shown creates their own version in the body so they require lower doses than many of the regimens required with current mRNA vaccines.

Also Read :  IonQ Stock: Building Technology For Quantum Computing

He is currently working on his own mRNA vaccine for COVID-19, influenza, and other respiratory diseases.

CSL Chief Medical Officer Dr Bill Mezzanotte said this collaboration with Next Generation mRNA is another example of the company’s pursuit of disruptive innovation.

“We look forward to working with Arcturus to shape the future of influenza vaccine therapy and to use this exciting scientific approach to develop and commercialize vaccines for other infectious diseases and -fly flies without need,” Mezzanotte, who also needs. spent 16 years at AstraZeneca, said.

CSL was established in Australia in 1916 to meet the nation’s health needs in the midst of the First World War. A century later, it has become the world leader in vaccinating rare and serious diseases, including influenza, polio, and other infectious diseases. .

Also Read :  Layoffs at big tech a boon for climate change firms

Surgeons warn that anti-mRNA drugs are killing men

The Doctor General of Florida Joseph A. Ladapo recently warned that the vaccine against COVID-19 mRNA increases the risk of death from heart problems, especially in men.

“This study found that there was an 84 percent increase in the number of heart-related deaths among men 18-39 years of age in the 28 days following the mRNA vaccine,” he said.

“This is not the first study to identify an increased risk of cardiovascular outcomes with a COVID-19 mRNA vaccine.”

Also Read :  South Korea inflation, U.S. jobs report, China Covid-zero

However, in a media briefing, Twitter removed some of the information from the surgeon.

Meanwhile, a lot of data coming out in various journals has been discredited.

For example, a recent medical journal found that it falsified data in a peer-reviewed study on vaccination by aggregating those with immunity from COVID-19 with data on those who received the vaccine.

Jessie Zhang

Follow along

Jessie Zhang is a Sydney-based journalist covering Australian news, focusing on health and the environment. Contact her at [email protected]


Leave a Reply

Your email address will not be published.

Related Articles

Back to top button